Hepaxane

Hepaxane is a prescription medication that contains the active ingredient enoxaparin sodium, a low‑molecular‑weight heparin, provided as an injectable solution for subcutaneous, intravenous, or haemodialysis administration. It is marketed in the European Union and is classified as an anticoagulant used to reduce the risk of blood clot formation in clinical settings. It is supplied in sterile vials and must be administered by a healthcare professional.

Hepaxane is used in clinical practice to prevent and treat thromboembolic conditions where anticoagulation is indicated.

- Prophylaxis of deep vein thrombosis (DVT) in patients undergoing orthopedic surgery or prolonged immobilization. - Treatment of acute DVT and pulmonary embolism, including extension therapy. - Prevention of clot formation during haemodialysis procedures. - Anticoagulation in patients with unstable angina or non‑ST elevation myocardial infarction when combined with other antiplatelet agents. - Bridging anticoagulation for patients transitioning between oral anticoagulants and surgical procedures.

The safety profile of enoxaparin sodium reflects the pharmacologic activity of low molecular weight heparins and includes both frequent and rare adverse events.

Common: - Minor bruising or bleeding at the injection site. - Small amounts of nosebleed or gum bleeding. - Mild skin irritation or erythema around the administration area.

Serious: - Significant bleeding such as gastrointestinal hemorrhage or intracranial bleed. - Thrombocytopenia, including heparin‑induced thrombocytopenia (HIT). - Allergic reactions ranging from rash to anaphylaxis.

Before initiating Hepaxane therapy, clinicians should evaluate patient‑specific factors and monitor for conditions that may increase the risk of bleeding or other complications.

- History of active bleeding, recent surgery, or trauma. - Severe renal impairment, as drug clearance is reduced. - Concomitant use of other anticoagulants, antiplatelet agents, or thrombolytics. - Known hypersensitivity to enoxaparin, heparin, or any excipients. - Pregnancy and lactation status should be assessed, as safety data are limited. - Baseline platelet count and periodic monitoring to detect thrombocytopenia.

Enoxaparin sodium can interact with several medications, potentially altering anticoagulant effect or increasing bleeding risk.

Avoid: - Other injectable or oral anticoagulants (e.g., warfarin, direct oral anticoagulants) without appropriate dose adjustment. - Non‑steroidal anti‑inflammatory drugs (NSAIDs) and aspirin at high doses. - Systemic thrombolytic agents (e.g., alteplase, streptokinase).

Use with caution: - Antiplatelet drugs such as clopidogrel or ticagrelor. - Selective serotonin reuptake inhibitors (SSRIs) and other serotonergic agents. - Concomitant corticosteroids or other agents that may impair platelet function.